SymBio Pharmaceuticals, Ltd.: Series E $24M

Posted in I - Series E, Q - 1Q11, R - INTERNATIONAL, X - Hematology, X - Oncology

SymBio Pharmaceuticals (Japan) a commercial-stage pharmaceutical company focused on non-Hodgkin’s lymphoma, multiple myeloma and other hematological indications, closed a $24M Series E financing. Participants include Cephalon, Nippon Venture Capital, SMBC Venture Capital, MBL Venture Capital and JAFCO.

Jan

2011

Noxxon Pharma, AG: Series D $2.6M

Posted in I - Series D, Q - 4Q10, R - INTERNATIONAL, X - Aptamer, X - Hematology, X - Inflammation

Noxxon Pharma (Germany) a clinical-stage biopharmaceutical company focused on the development of aptamers for the treatment of inflammation and hematological indications closed a $2.6M Series D financing, bringing the total round to $42.6M. Participants include NGN Capital, TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, Seventure Partners, VC Fonds Technologie Berlin, Dow Venture Capital, [...]

Nov

2010

Helix Therapeutics, Inc.: Series A $2.5M

Posted in I - Series A, Q - 4Q10, R - NORTH EAST, X - Hematology, X - Immunology, X - Lysosomal Storage, XX - CT

Helix Therapeutics (New Haven, CT) a preclinical-stage company developing triplex-forming oligonucleotides to target genome modification with a focused on hemoglobin, immune and lysosomal storage disorders, closed a $2.5M Series A financing. Participants include Canaan Partners and Connecticut Innovations.

Nov

2010

aTyr Pharma, Inc.: Series C $23M

Posted in I - Series C, Q - 4Q10, R - WEST, X - Hematology, X - Immunology, X - Metabolism, XX - CA

aTyr Pharma (San Diego, CA) a preclinical-stage biopharmaceutical company focused on immune, metabolic and hematologic indications, closed a $23M Series C financing. Participants include Domain Associates, Alta Partners, Cardinal Partners and Polaris Ventures.

Jul

2010

Noxxon Pharma, AG: Series D $40M

Posted in I - Series D, Q - 2Q10, R - INTERNATIONAL, X - Aptamer, X - Hematology, X - Inflammation

Noxxon Pharma (Germany) a clinical-stage biopharmaceutical company focused on the development of aptamers for the treatment of inflammation and hematological indications closed a $40M Series D financing. Participants include NGN Capital, TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, Seventure Partners, VC Fonds Technologie Berlin, Dow Venture Capital, Fcp Medical BioHealth-Trends, IBG Beteiligungsgesellschaft Sachsen-Anhalt [...]

Sep

2009

aTyr Pharma, Inc.: Series C $12M

Posted in I - Series C, Q - 3Q09, R - WEST, X - Autoimmune, X - Hematology, X - Inflammation, X - Metabolism, XX - CA

aTyr Pharma (San Diego, CA) a preclinical-stage biopharmaceutical company focused on inflammation, autoimmune, hematopoietic and metabolic disorders, closed a $12M Series C financing. Participants include Alta Partners, Cardinal Partners and Polaris Ventures.

Dec

2008

Quotient Bioscience Group, Ltd.: Series B $53M

Posted in I - Series B, Q - 3Q08, R - INTERNATIONAL, X - Diagnostic, X - Hematology

Quotient Bioscience Group (United Kingdom) a provider of bioscience analytics and safety evaluation services, closed a $53M Series B financing. Participants include TA Associates.

to top of page...